Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Jeito Capital
BioCentury | Mar 29, 2025
Finance
Autoimmune play Hillstar takes wing with $67M series A: Finance Report
Plus: Novo Holdings, Jeito lead week’s largest A round for VIB company Augustine — and more
BioCentury | Mar 15, 2025
Editor's Commentary
The NewCo model spurs debate, but it’s about more than money — a Perspective
Expanding the dealmaker’s toolkit to bring Asian innovation to the West
BioCentury | Mar 4, 2025
Deals
Kyorin picks Novartis amid innovative push; Abbvie taps Gubra for obesity: Deals Report
Plus: Hummingbird/Callio, Bridgene/Takeda, Magnet/Lilly, Gensaic/Novo, and more
BioCentury | Mar 3, 2025
Deals
The dealmaking at the heart of the NewCo boom
Formed with Hummingbird assets, $187M, Callio brings trend to Singapore
BioCentury | Nov 23, 2024
Finance
Latest Jeito bet positions European VC for fourth exit
Mega-round for Alentis spotlights French firm’s investment style
BioCentury | Nov 15, 2024
Finance
Syncona building Slingshot incubator; Trace launches with $101M
BioCentury’s Financial Report also features venture rounds for Alentis and Metsera; follow-ons for Zai Lab and 89bio
BioCentury | Jul 18, 2024
Finance
Venture Report: Five biotechs raise nearly $800M in two-day flurry
Plus: New capital for CytoReason, Truvian and Renalys
BioCentury | Jun 4, 2024
Deals
Biotech M&A, Biosecure expands & ASCO update: a BioCentury podcast
An M&A quartet. House China committee’s new focus. Colorectal cancer immunotherapies.
BioCentury | May 29, 2024
Deals
Clinical readout spurred Merck’s $1.3B takeout of VC-backed ophthalmic play EyeBio
In milestone-heavy deal worth up to $3B total, the pharma makes a big commitment to late-stage candidate for retinal diseases
BioCentury | May 22, 2024
Deals
Biogen’s ‘pick and choose’ strategy in immunology leads to $1B HI-Bio takeout
Continuing diversity push under Viehbacher, Biogen obtains two programs spun out from MorphoSys, backed by Arch, Monograph, Jeito and others
Items per page:
1 - 10 of 56